Many large US company stocks appear to be expensive. Here are other investment opportunities heading into the new year.

People over 50 have long had the ability to make additional “catch-up” contributions to their 401 (k)s, as well as 403 (b)s ...

Stocks resumed their upward march last week, rising 2.1% as the U.S. reporting season drew to a close. At a sector level ...

Summit Materials Inc.'s stock (SUM) was down 1.5% in regular trading on Monday as it fell back from speculative prices after announcing last month that it received a non-binding merger proposal.

Manufacturing activity in Texas was mostly flat in November, with production continuing to struggle but expectations rising post-election. The Texas Manufacturing Outlook Survey for current business ...

The benchmark 10-year Treasury yield, used to finance much of the U.S. economy, was on pace for its biggest one-day drop since Aug. 2, according to Dow Jones Market Data. Back then, yields plunged in ...

The Carlyle Group has built a solid position in the alternative-asset management industry. It relies on its reputation, broad product portfolio, investment performance history, and cadre of dedicated ...

Sea and Spotify saw the largest valuation bumps among US-listed stocks covered by Morningstar analysts.

As crypto enters the second phase of a bull market, ether is likely to see a boost, according to Jupiter Zheng, partner of liquid funds and research at Hashkey Capital. Historically, ether has tended ...

Investors receive short notice that earnings won't be reported on Tuesday as expected, but will be released by Dec. 11 Shares of Macy's Inc. took a hit Monday, after the department-store chain said it ...

Along with his upgrade of Snowflake, Ives raised his rating on Elastic N.V.'s stock (ESTC) to outperform from neutral and set a price target of $135 a share. Elastic's stock rose about 4.2%.

Cassava Sciences Inc.'s stock tumbled 85% Monday to put it on track for its biggest-ever one-day decline, after the clinical-stage biotech company said a trial of a treatment for mild to moderate ...